Servier is a French pharmaceutical company that specializes in research, development, production, and marketing of innovative medications. Founded in 1954 by Dr. Jacques Servier, the company is headquartered in Suresnes, France, a suburb of Paris.

Servier's main focus is on cardiology, oncology, rheumatology, and diabetes. The company offers a wide range of pharmaceutical products, including prescription drugs, generic medications, and over-the-counter treatments. Its portfolio includes drugs for heart disease, cancer, diabetes, and neurological disorders, among others.

The company invests heavily in research and development to continuously bring new treatments to the market. Operating on a global scale, Servier has a significant presence in more than 150 countries. The company has established subsidiaries and joint ventures in various regions, including Europe, North America, Latin America, Africa, and Asia.

Some of its notable subsidiaries include Egis Pharmaceuticals (Hungary), Bioreva (France), and Servier Laboratories (Australia). Servier has solidified its market position as a key player in the pharmaceutical industry. The company consistently ranks among the top global pharmaceutical companies in terms of sales.

In recent years, Servier has been growing and expanding its market share through strategic partnerships and acquisitions. Notably, in 2017, Servier acquired Shire's oncology division, helping to further strengthen its presence in the oncology sector. In terms of major events, Servier faced a significant setback in 2013 due to a safety scandal involving its diabetes drug Mediator, which was withdrawn from the market.

However, the company has since made efforts to improve its drug safety processes and regain public trust. Currently, Servier continues to focus on innovation and collaboration. The company actively partners with academic institutions, research organizations, and other pharmaceutical companies to develop new treatment options.

Servier's dedication to research and development has resulted in a robust pipeline of potential drug candidates across various therapeutic areas. Overall, Servier remains a prominent player in the global pharmaceutical industry with a strong market position and an unwavering commitment to improving patient lives through its innovative medications